Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management

Core Insights - The article discusses the treatment of residual dizziness following physical repositioning procedures for benign paroxysmal positional vertigo (BPPV), highlighting the role of betahistine and its intranasal formulation AM-125 developed by Altamira Therapeutics [7][9]. Group 1: BPPV and Its Impact - BPPV is the most common type of vertigo, accounting for 17% to 42% of all diagnosed cases, with healthcare costs in the U.S. approaching $2 billion annually [8]. - Approximately 31% to 61% of BPPV patients experience residual dizziness after treatment, which can significantly affect their quality of life [7][8]. - Almost 86% of BPPV patients report interruptions to daily activities and lost workdays due to their condition [8]. Group 2: Betahistine and Its Formulations - Betahistine is recognized as a standard treatment for dizziness and vertigo, marketed worldwide except in the U.S., but its oral formulation has limited clinical utility due to poor bioavailability [4][7]. - AM-125, an intranasal formulation of betahistine, has demonstrated 5 to 29 times higher bioavailability compared to the oral version, making it a promising treatment option for U.S. patients [5][9]. - The combination of physical repositioning procedures with betahistine treatment has shown a significantly greater reduction in dizziness handicap compared to the procedure alone, with a p-value of 0.001 [2][6]. Group 3: Altamira Therapeutics and Strategic Focus - Altamira Therapeutics is pivoting towards RNA delivery technology while developing AM-125 as part of its legacy assets [5][9]. - The company is exploring partnerships or divestments for AM-125 to enhance its market reach and availability in the U.S. [7][9]. - Altamira's current projects include two flagship siRNA programs for cancer and rheumatoid arthritis, both in preclinical development [5].